This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durata Therapeutics, Inc. Reports Second Quarter 2013 Financial Results

CHICAGO, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2013.

Q2 2013 Highlights and Recent Events

Accomplishments include the following:
  • Completed an equity offering in April, resulting in approximately $54.1 million of net proceeds before deducting costs payable by us
  • Presented new data demonstrating in vitro potency of dalbavancin against bacterial pathogens at the 23rd Annual ECCMID Meeting
  • Elected Paul A. Friedman, M.D. to the Board of Directors
  • Concluded pre-New Drug Application ("NDA") clinical and CMC meetings with the Food and Drug Administration ("FDA")
  • Confirmed process and timeline for NDA submission with the FDA

"We are pleased to reaffirm the timing of the submission of both the NDA and the Marketing Authorization Application ("MAA")," said Paul Edick, Chief Executive Officer of Durata Therapeutics, Inc. "Based on discussions with the FDA, including pre-NDA meetings in which both clinical and manufacturing data were discussed, we intend to submit to the FDA our initial NDA submission in late September. The MAA submission also remains on track to file with the European Medicines Agency ("EMA") by year-end." Mr. Edick continued, "Our cash position following our $54 million equity raise remains strong and will enable us to successfully launch dalbavancin in the U.S. in the second half of 2014."

Financial results for the quarter ended June 30, 2013

As of June 30, 2013, we had cash and cash equivalents plus short-term investments of $83.5 million, compared to $45.4 million at December 31, 2012. The increase was primarily due to the Company's equity offering in the second quarter.

Net loss for the three months ended June 30, 2013 (the "2013 Quarter") was $18.8 million, compared to a net loss of $19.2 million for the three months ended June 30, 2012 (the "2012 Quarter").

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,761.28 +15.30 0.09%
S&P 500 2,112.74 +4.11 0.19%
NASDAQ 5,147.3310 +18.5460 0.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs